Yancheng Kaili Pharmaceutical Co., Ltd. was established in 2010 and is a comprehensive pharmaceutical enterprise that integrates the research and development, production, and sales of chemical raw materials, medical devices, and biopharmaceuticals. Located on the coast of the Yellow Sea, Binhai County Economic Development Zone Coastal Industrial Park is a provincial-level economic development zone. It is a 30 minute drive from G15 (Shenhai Expressway) and Binhai Port High speed Railway Station, and a 1.5-hour drive from Huai'an Lianshui Airport, Lianyungang Baitabu Airport, and Yancheng Nanyang International Airport, with convenient transportation.

The company covers an area of 100 acres with a total investment of over 200 million RMB. At present, the company has about 200 employees, of which more than 30% are middle and senior technical personnel. The management team of the company has good professional competence, and the employees have high cultural quality, safety and environmental protection, and GMP awareness. At the same time, the overall personnel are stable.

The predecessor of the company, Wuxi Kaili Pharmaceutical Co., Ltd., was founded in 1988 and obtained the domestic GMP certificate for active pharmaceutical ingredients in April 2003. In the same year, it passed the European Certificate of Suitability (COS) and on-site certification by the US FDA. In 2010, Yancheng Kaili Pharmaceutical Co., Ltd. was invested and built in Binhai County, Yancheng City, Jiangsu Province in order to cooperate with the local government's the Taihu Lake Lake governance policy.

In May 2016, the company introduced strategic investor Shanghai Baolong Pharmaceutical Co., Ltd., further enhancing the overall core competitiveness of the company.

In order to form a complete upstream and downstream industrial chain from raw materials to finished drug formulations, Yancheng Kaili Pharmaceutical invested in the establishment of Yancheng Kailong Pharmaceutical Co., Ltd. in August 2017. Yancheng Kailong Pharmaceutical Co., Ltd. is a comprehensive formulation enterprise mainly engaged in research and development, production, and sales of medical devices and finished drug formulations.

At present, the company's main products include active pharmaceutical ingredients such as cimetidine, nifurtier, pralofen, ketoconazole, paclitaxel palmitate, and other non active pharmaceutical ingredients. Among them, the active pharmaceutical ingredient cimetidine has passed the audit certification of China GMP/Japan PMDA/South Korea KFDA, and has obtained a pass to enter the Japanese and South Korean markets.

The company is a national "high-tech enterprise" Provincial level 'specialized, refined, unique and new enterprise', with over 20 invention patents. The company has internationally advanced production equipment and testing instruments, a scientific production management system, and a strict drug quality assurance system.

The company always adheres to the core values of "establishing the enterprise with morality, integrity-based, and co creation and sharing"; Adhere to the business philosophy of "safety and environmental protection first, economic benefits and social responsibility go hand in hand". The company cherishes every opportunity for cooperation and achievement honor, actively builds harmonious and win-win relationships between the enterprise, employees, and customers, and hopes to create brilliance with partners!